Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT(1D) agonist sumatriptan

Liat Stern, Joseph Zohar, Rivka Cohen, Yehuda Sasson

Research output: Contribution to journalArticlepeer-review

Abstract

The serotonergic system has been implicated in both the aetiology and pharmacological treatment of obsessive compulsive disorder. In pharmacological challenge tests, mCPP, a 5-HT agonist, with an affinity for 5HT(2C) as well as 5HT(1A) and 5HT(1D), receptors, was associated with a transient exacerbation of obsessive compulsive symptoms. Chronic administration of mCPP was found to bring about some relief of these symptoms. Sumatriptan is an antimigraine agent, which interacts most potently with 5HT(1D) receptors. In the cases to be presented, we report the effects of chronic administration of Sumatriptan to three severe, treatment resistant, OCD patients. Following chronic administration of sumatriptan, these patients, who have been resistant to any former pharmacological treatment, responded with an improvement in their depression and a modest reduction in their obsessive compulsive symptoms. Copyright (C) 1998 Elsevier Science B.V./ECNP.

Original languageEnglish
Pages (from-to)325-328
Number of pages4
JournalEuropean Neuropsychopharmacology
Volume8
Issue number4
DOIs
StatePublished - 1 Dec 1998
Externally publishedYes

Keywords

  • Drug resistant
  • Obsessive compulsive disorder
  • Sumatriptan treatment

Fingerprint

Dive into the research topics of 'Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT(1D) agonist sumatriptan'. Together they form a unique fingerprint.

Cite this